Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

act is significantly reduced and, as the iron is retained within the product if it is not absorbed, it is expected this will significantly reduce the risk of unwanted side effects within the gastrointestinal tract.

The international, multicentre, randomised, double-blind and placebo controlled AEGIS 1 and AEGIS 2 studies will investigate the potential of ST10 as a twice-daily treatment of IDA in subjects with Ulcerative Colitis (UC) or Crohn's disease respectively where oral ferrous preparations have failed or cannot be used.  The studies are each enrolling 120 patients and will measure patients' change in haemoglobin concentration from baseline to week 12.  Initial results from both studies are expected to be reported in late 2012 and, if positive, will be promptly followed by filings of marketing authorisation applications in key pharmaceutical markets.  In addition, Shield is planning to initiate a Phase 3 study of ST10 for the treatment of IDA in patients with chronic kidney disease in 2012.  

Data provided by IMS suggests that the iron market was worth $2.4 billion in 2010, of which 55% of revenues were generated from oral iron therapies.

There are currently no curative treatments available for UC or Crohn's and so treatment options are restricted to controlling symptoms, maintaining remission and preventing relapse.  IDA in both is a chronically debilitating disorder which has a significant impact on patients' quality of life and, as a result, its treatment is an important aspect of disease management.  Characteristic symptoms of IDA include chronic fatigue, headache and subtle impairment of cognitive function.  Up to one third of subjects with UC and Crohn's suffer from recurrent anaemia, with hospitalisation required in severe cases.

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an ind
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... , ... , ... series documenting,simple protocols for culturing cells in a BioFlo 110,benchtop ... impellers,and control modules to enable growth of a wide variety,of cultures, including ...
... Olive, Ph.D. , Molecular Biology Department , ... Lincoln, NE 68504 , , ... , Optical imaging is ... of a living animal. While several optical imaging modalities employing,fluorescent proteins or bioluminescent reporter ...
... , ... , , ... HPLC by utilizing the Prominence,hardware series. In this respect, we are ... while providing high,reliability and expandability not available with other fast,LC systems., ...
Cached Biology Technology:Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 2Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 3Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 4Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 5Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 6Near Infrared Technology and Optical Agents For Molecular Imaging 2Near Infrared Technology and Optical Agents For Molecular Imaging 3Near Infrared Technology and Optical Agents For Molecular Imaging 4Near Infrared Technology and Optical Agents For Molecular Imaging 5Near Infrared Technology and Optical Agents For Molecular Imaging 6Near Infrared Technology and Optical Agents For Molecular Imaging 7Prominence UFLC 2Prominence UFLC 3Prominence UFLC 4Prominence UFLC 5Prominence UFLC 6Prominence UFLC 7Prominence UFLC 8
(Date:4/22/2014)... (FASEB) has released updated factsheets for fiscal ... Institutes of Health (NIH) benefits each of the 50 ... make these factsheets available to help citizens and policymakers ... FASEB President, Margaret K. Offermann, MD, PhD. NIH is ... investing $29.2 billion in FY 2013 in medical research, ...
(Date:4/22/2014)... Analyzing thousands of breeding bird surveys sent in ... Canada over 35 years, wildlife researchers report that most ... northward or toward higher elevation in response to climate ... means that most previous studies of potential climate change ... or the other have likely underestimated the effects of ...
(Date:4/22/2014)... French . , ... complete genome and subsequent phylogenetic analysis show that the ... is distinct from strains previously identified in the Democratic ... linked the laboratory confirmed cases with the initial deaths ... is a lethal, highly contagious virus for which there ...
Breaking Biology News(10 mins):Wildlife response to climate change is likely underestimated, experts warn 2Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2
... work. Biology researchers at Lewis & Clark College and ... ancient transfer of a toxin between ancestors of two ... remains as how the toxin passed between the two ... journal Bioinformatics, 22(3): 264-268, in an article titled "Lateral ...
... marijuana or its active cannabinoid ingredient alleviates symptoms ... researchers have found that the brain's natural "endocannabinoids" ... to alleviate neuronal damage. However, scientists have not ... own immune system. , Now, experiments by Oliver ...
... Research Associate at the Stowers Institute for Medical Research, ... investigator with the Howard Hughes Medical Institute, have demonstrated ... is expressed in a cyclic fashion during the formation ... embryo. , The findings, which were published in ...
Cached Biology News:Evolution mystery: Spider venom and bacteria share same toxin 2Brain's own cannabis compound protects against inflammation 2Stowers scientists demonstrate mechanism of vertebral formation 2
...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
Biology Products: